AMOTL2

Across TCGA pan-cancer cohorts, AMOTL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AMOTL2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AMOTL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMOTL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where AMOTL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.441	1.000	.002	18	view →
LUAD	OS	Median	III,IV	0.295	0.819	.002	13	view →
HNSC	DFS	Median	IV	0.844	0.523	.002	11	view →
PDAC	OS	Median	II,III,IV	0.651	0.270	.012	4	view →
GBM	DFS	Median	All	0.300	0.438	.027	3	view →
LSCC	OS	Median	II,III,IV	0.899	1.000	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AMOTL2–CCRCC (DFS)

Open the CCRCC breakdown →